DL2

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Solid TumorLocally Advanced Breast Cancer

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

1

Fludara

Sanofi

Preclinical

12

DATROWAY

Daiichi Sankyo

Preclinical

13

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

24

DL2

Sun Pharma Advanced Research Company Limited

Phase 2

15

Navmi

SSummit Therapeutics

Preclinical

16

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

17

Tulmimetostat

Novartis

Preclinical

18

PD-1 Inhibitor

Johnson & Johnson

Preclinical

19

SAR445877

Sanofi

Preclinical

110

Sacituzumab Govitecan-Hziy

Gilead

Preclinical

1Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Extensive-stage Small-cell Lung Cancer1 trial

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

Active, not recruiting·BioNTech·Phase 2·NCT06449209·110 enrolled

Solid Tumor1 trial

A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors

Recruiting·Sun Pharma Advanced Research Company Limited·Phase 1·NCT07042100·177 enrolled

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting·BioNTech·Phase 2·NCT06449222·83 enrolled

Details

Drug Info

Related News